Cargando…
Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90).
Infusional 5-fluorouracil in advanced breast cancer has been associated with improved clinical response rates when compared with conventional bolus therapy. As a first line of chemotherapy in proven metastatic breast carcinoma, 258 women were randomly assigned to receive FAC consisting of 5-fluorour...
Autores principales: | Pierga, J. Y., Jouve, M., Asselain, B., Livartowski, A., Beuzeboc, P., Diéras, V., Scholl, S., Dorval, T., Palangié, T., Garcia-Giralt, E., Pouillart, P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150182/ https://www.ncbi.nlm.nih.gov/pubmed/9652764 |
Ejemplares similares
-
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer
por: Pierga, J-Y, et al.
Publicado: (2000) -
The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells
por: Reis-Mendes, Ana, et al.
Publicado: (2019) -
Postirradiation Sarcoma: Clinicopathologic Features and Role of Chemotherapy in the Treatment Strategy
por: des Guetz, Gaetan, et al.
Publicado: (2009) -
Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.
por: Pierga, J. Y., et al.
Publicado: (1997) -
Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
por: Pereira-Oliveira, Maria, et al.
Publicado: (2019)